Healthcare / Drug Manufacturers - Specialty & GenericTokyo
$765.00
-12.00 (-1.54%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $2.7B · quality 81.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
61/100
B
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$32.2B
P/E
8.8x
↓EV/EBITDA
3.8x
↓ROE
11.8%
↑Gross Margin
30.0%
↓Debt/Equity
0.11
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
+7.5%
FCF CAGR
+7.9%
FCF margin
17.3%
FCF / Net income
1.30x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $22.13B · net income $2.95B · FCF $3.83B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $22.13B | $22.13B | $22.05B | $20.35B | $17.82B |
| Net Income | $2.95B | $2.95B | $2.69B | $2.36B | $2.14B |
| EBITDA | $5.10B | $5.10B | $4.79B | $4.44B | $4.05B |
| EPS | 74.14 | 74.14 | 67.83 | 59.55 | — |
| Gross Margin | 30.0% | 30.0% | 29.2% | 29.2% | 31.1% |
| Operating Margin | 19.8% | 19.8% | 19.3% | 18.7% | 19.0% |
| Net Margin | 13.3% | 13.3% | 12.2% | 11.6% | 12.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.11 | 0.11 | 0.15 | 0.19 | 0.23 |
| Current Ratio | 4.22 | 4.22 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $3.83B | $3.83B | $2.74B | $2.09B | $3.05B |
| Returns | |||||
| ROE | 11.8% | 11.8% | 12.8% | 12.6% | 12.8% |
| Valuation | |||||
| P/E | 8.77 | 8.77 | 9.52 | 11.81 | — |
| EV/EBITDA | 3.78 | 3.78 | 3.75 | 5.00 | 5.57 |
| P/B | 1.21 | 1.21 | 1.22 | 1.49 | 1.62 |
| Growth & Yield | |||||
| Revenue Growth | 0.4% | 0.4% | 8.3% | 14.2% | — |
| EPS Growth | 9.3% | 9.3% | 13.9% | — | — |
| Dividend Yield | 2.3% | 2.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-2.9%
EPS terminal req.
$67.88
Spread vs growth
12.2%
5Y implied EPS CAGR
2.1%
EPS terminal req.
$82.14
Spread vs growth
7.2%
10Y implied EPS CAGR
6.0%
EPS terminal req.
$132.28
Spread vs growth
3.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+16.3%
Start / end P/E
9.9x → 10.3x
EPS bridge
67.83 → 74.14
Residual
+0.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.